Sernivo

Indications

Sernivo is specifically indicated for the treatment of mild to moderate plaque psoriasis. It is approved for use in adults who are 18 years of age or older.

Symptoms Treated

This medication is used to relieve the physical discomforts associated with skin flare-ups. It helps manage:

• Redness and swelling: Reduces the inflammation that causes skin to appear red and feel tender.
• Itching: Calms the irritation and persistent urge to scratch the skin.
• Scaling and flaking: Addresses the buildup of dry, thick, or crusty patches of skin typical of plaque psoriasis.

As a topical corticosteroid, Sernivo is intended for application directly to the affected skin areas to help control symptoms during a flare-up. It is generally used for a limited duration as determined by a healthcare provider.

How Sernivo Works

Sernivo contains betamethasone dipropionate, a high-potency corticosteroid. It works by mimicking the effects of natural hormones in the body to manage skin irritation and inflammation.

When applied to the skin, the medication performs several key actions:

• Reducing Inflammation: It blocks the production of chemicals that cause the skin to become red, swollen, and painful.
• Relieving Itch: By calming the skin's immune response, it reduces the sensation of itching, also known as an antipruritic effect.
• Narrowing Blood Vessels: It causes small blood vessels in the skin to constrict, which helps decrease redness and fluid buildup in the treated area.

While the exact biological process is not fully understood, it is generally thought that the medication enters skin cells and triggers the production of specific proteins that prevent the release of substances that cause inflammation.

Common Side Effects

The most frequent side effects of Sernivo occur at the site of application. These may include:

• Burning, stinging, or itching
• Skin redness or irritation
• Dryness or cracking of the skin
• Thinning of the skin or stretch marks
• Acne or tiny red bumps on the skin
• Inflamed hair follicles
• Changes in skin color

Serious Side Effects

In some cases, this medication can be absorbed through the skin, leading to more severe complications. Seek medical help for:

• Severe skin reactions, such as blistering, peeling, or signs of infection
• Vision changes, including blurred vision, eye pain, or seeing halos
• Signs of high blood sugar, such as increased thirst, frequent urination, or fruity breath odor
• Symptoms of adrenal suppression, including extreme fatigue, muscle weakness, dizziness, or unexplained weight loss
• Swelling in the face, ankles, or feet

The risk of side effects is higher when the medication is used over large areas of the body, for long periods, or with bandages that cover the treated area. Children may be more sensitive to the systemic effects of topical corticosteroids.

Systemic Absorption and Hormonal Effects

Because Sernivo is a high-potency topical steroid, it can be absorbed into the bloodstream. This may cause suppression of the hypothalamic-pituitary-adrenal (HPA) axis, which regulates hormone production. Risk factors for systemic absorption include:

• Use over large surface areas of the body.
• Prolonged use beyond the recommended four-week limit.
• Use of occlusive dressings, such as bandages or plastic wrap, over the treated area.

Systemic absorption can also lead to Cushing's syndrome, high blood sugar (hyperglycemia), and the presence of sugar in the urine (glucosuria).

Local Skin Reactions

Applying Sernivo may cause local adverse reactions, including skin thinning (atrophy), stretch marks (striae), spider veins (telangiectasia), burning, itching, or dryness. If significant irritation or allergic contact dermatitis occurs, treatment should be stopped. It is generally recommended to avoid applying this medication to the face, scalp, underarms, or groin area.

Vision Concerns

Topical corticosteroids can increase the risk of developing cataracts or glaucoma. Care should be taken to avoid getting the spray in or near the eyes. If visual symptoms like blurred vision occur, a medical evaluation may be necessary.

Pediatric Precautions

Children and adolescents may be more susceptible to systemic toxicity and HPA axis suppression than adults. This is due to their larger skin surface area relative to their body weight. Use in pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen.

Skin Infections

If a skin infection is present or develops during treatment, an appropriate antifungal or antibacterial agent should be used. If the infection does not respond promptly, Sernivo should be discontinued until the infection is properly controlled.

Pregnancy

The safety of Sernivo during pregnancy has not been fully established. As a high-potency topical corticosteroid, it should be used during pregnancy only if the potential benefits outweigh the potential risks to the fetus.

If you are pregnant or planning to become pregnant, talk to your healthcare provider. If treatment is necessary, it is usually recommended to use the lowest effective dose for the shortest possible duration.

Breastfeeding

It is unknown if betamethasone dipropionate passes into breast milk when applied to the skin. If you are breastfeeding, consult your doctor before using this medication.

To protect the nursing infant, follow these safety measures:

• Do not apply Sernivo to the breast or nipple area.
• Ensure the infant does not come into contact with treated skin.
• Wash your hands thoroughly after each application.

Dosage Forms

Sernivo is supplied in the following form and strength:

• Topical Spray Emulsion: 0.05%

The medication is typically provided in spray bottles designed for application to affected skin areas. It is formulated as an emulsion, which is a mixture of oil and water.

FDA Approval and Indications

Sernivo (betamethasone dipropionate) spray, 0.05%, is approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of mild to moderate plaque psoriasis. It is specifically indicated for use in adult patients.

Regulatory Guidelines for Use

The FDA-approved labeling for Sernivo includes specific safety guidelines to minimize the risk of systemic absorption and side effects, such as adrenal suppression. Key regulatory considerations include:

• Treatment Duration: Use is generally limited to a maximum of four consecutive weeks. Treatment should be discontinued once the skin condition is controlled.
• Age Restrictions: The safety and effectiveness of Sernivo have not been established in pediatric patients. It is not approved for use in individuals under 18 years of age.
• Application Limits: The medication should not be used with occlusive dressings, such as bandages or plastic wrap, unless specifically directed by a healthcare provider. It is also not intended for use on the face, scalp, underarms, or groin.

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements associated with Sernivo.

Insurance Coverage

As a brand-name prescription medication, Sernivo may be subject to different coverage levels depending on your health insurance plan. Insurance companies often place medications into tiers, which determines your out-of-pocket copayment. Some plans may require prior authorization from a healthcare provider before they will cover the cost of this specific spray formulation.

Pharmacy Variations

The retail price of Sernivo can vary between different pharmacies. Patients may find different pricing at local retail chains, independent pharmacies, or through mail-order services provided by their insurance company.

Generic Availability

The active ingredient in Sernivo, betamethasone dipropionate, is widely available in generic forms such as creams, ointments, and lotions. However, Sernivo is a specific brand-name spray. While generic versions of betamethasone dipropionate are generally less expensive than brand-name products, they may not be available in the same spray delivery system as Sernivo. You should consult with a pharmacist or healthcare provider to determine if a more cost-effective generic version is appropriate for your condition.